Radiation proctitis future or investigational therapies
Recent studies on chronic radiation proctitis suggested 2.12- to 7.31-fold higher expression levels of angiogenin, fibroblast growth factor 1 (FGF1), endoglin, matrix metalloproteinase (MMP)-8, urokinase-type plasminogen activator (uPA) and maspin in radiation proctitis tissues compared with normal rectal mucosa.Based on the this study, it has been concluded that Inhibitors of angiogenic factors such as angiogenin and FGF1 may be effective for treating radiation proctitis in future.[1][2]
Radiation proctitis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Radiation proctitis future or investigational therapies On the Web |
American Roentgen Ray Society Images of Radiation proctitis future or investigational therapies |
FDA on Radiation proctitis future or investigational therapies |
CDC on Radiation proctitis future or investigational therapies |
Radiation proctitis future or investigational therapies in the news |
Blogs on Radiation proctitis future or investigational therapies |
Risk calculators and risk factors for Radiation proctitis future or investigational therapies |
References
- ↑ Takeuchi, Hisashi; Kimura, Tetsuo; Okamoto, Koichi; Aoyagi, Eriko; Miyamoto, Hiroshi; Kaji, Masako; Takenaka, Hidetaka; Okamura, Seisuke; Sato, Yasushi; Kato, Junji; Okahisa, Toshiya; Takayama, Tetsuji (2011). "A mechanism for abnormal angiogenesis in human radiation proctitis: analysis of expression profile for angiogenic factors". Journal of Gastroenterology. 47 (1): 56–64. doi:10.1007/s00535-011-0470-2. ISSN 0944-1174.
- ↑ Babb RR (1996). "Radiation proctitis: a review". Am J Gastroenterol. 91 (7): 1309–11. PMID 8677984.